Clinical trials
Therapy clinical trials
Below are recruiting therapy clinical trials, each written for real people, not researchers. We’re tracking 7,173 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06794086RecruitingPhase 3
SBRT and immunotherapy for colorectal cancer liver metastases
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
Guangzhou, GuangdongAges 18–75 - NCT06793306Enrolling by invitation
Breast cancer study comparing younger and older patients
This trial looks at differences between younger and older breast cancer patients to better understand the disease. If you had breast cancer between the ages of 18 and 75 and were treated in a Chinese hospital from 2000 to 2024, you might be able to help.
BeijingAges 18–75 - NCT06799351RecruitingPhase 2/Phase 3
Gut bacteria and nerve pain after chemo
This study looks at how bacteria in your gut (microbiome) might be linked to nerve pain from chemotherapy. It is for people who are already in the OzoParQT trial and will provide a stool sample to help understand this connection.
Las Palmas, Las PalmasAges 18 years+ - NCT06793189RecruitingPhase 2
Risk-Adapted Targeted Therapy for Untreated MZL
This trial tests a personalized treatment plan for people with newly diagnosed marginal zone lymphoma (MZL). The treatment is based on a risk score and aims to be more targeted than standard chemotherapy.
Shanghai, ChinaAges 18 years+ - NCT06796803RecruitingPhase 2/Phase 3
Combination therapy before surgery for liver cancer
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
Harbin, HeilongjiangAges 18–75 - NCT06795243Recruiting
Physical therapy for endometriosis and exercise adherence
This study tests whether physical therapy (exercise for your muscles) can help with endometriosis symptoms and how well people stick with the program. If you have endometriosis and can do light strength exercises, you may be able to join.
SevilleAges 18 years+ - NCT06802757RecruitingPhase 2
Study of posaconazole with immunotherapy and chemo for triple-negative breast cancer
This trial tests if adding posaconazole (an antifungal drug) to standard immunotherapy and chemotherapy before breast cancer surgery works better than just the standard treatment. It is for people with newly diagnosed, early-stage triple-negative breast cancer.
Jinan, ShandongAges 18–70 - NCT06794073Recruiting
Combination therapy for advanced liver cancer
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06801717Recruiting
Rosacea treatment with radiofrequency microneedling
This study tests using radiofrequency microneedling, a treatment that uses tiny needles and heat, to improve rosacea symptoms like redness and bumps. It may help if you have mild to moderate rosacea.
Miami Beach, FloridaAges 18 years+ - NCT06802406Recruiting
Nutrition support for transplant or cell therapy patients
This study tests a program to help patients who are getting a transplant or cell therapy and have trouble getting enough food. It provides nutrition resources to improve their health during treatment.
Stanford, CaliforniaAges 8–80 - NCT06793475Recruiting
Aponermin before CAR-T for multiple myeloma with extramedullary disease
This trial tests whether a drug called aponermin, given before CAR-T cell therapy, can help people with multiple myeloma that has come back or not responded to treatment and has spread to soft tissues (extramedullary disease). The goal is to make the CAR-T therapy work better.
BeijingAges 18 years+ - NCT06795230Recruiting
Arm exercise with blood flow cuffs for MS
This study tests a type of arm exercise that uses a blood pressure cuff to limit blood flow, aiming to improve arm function in people with multiple sclerosis. It may help if you have some arm weakness but no recent relapses or blood clotting issues.
Leganés, MadridAges 18 years+ - NCT04999904Recruiting
Balance training on uneven treadmill for unstable ankles
This study tests a special balance and movement training program on an uneven treadmill to improve ankle stability. It may help people whose ankles “give way” or keep getting sprained, but it requires specific timing after an ankle sprain and the ability to attend sessions for about 6 weeks.
Oceanside, CaliforniaAges 18–49 - NCT05530512Recruiting
Acupuncture for mild to moderate high blood pressure
This study tests whether acupuncture can help lower blood pressure in people with mild to moderate hypertension. You may be asked to join because you meet age and blood-pressure ranges and have a normal heart screening ECG.
Irvine, CaliforniaAges 45–75 - NCT06239818Recruiting
Light therapy for concussion recovery in teens
This trial tests whether a special light therapy (photobiomodulation) can help teenagers recover faster from a sports-related concussion. If you qualify, you will receive the light treatment in addition to your usual care, and researchers will track your symptoms and thinking skills over time.
Houston, TexasAges 13–18 - NCT06642220RecruitingPhase 2
Y-90 radioembolization for kidney cancer
This trial tests a procedure called Y-90 radioembolization for patients with kidney cancer tumors larger than 4 cm who cannot have or choose not to have surgery. The treatment delivers tiny radioactive beads through a blood vessel to the tumor to destroy cancer cells while limiting damage to healthy tissue.
London, OntarioAges 18 years+ - NCT06783335Recruiting
Cordella sensor for chronic heart failure
This trial studies a small sensor placed in the lung artery to help manage chronic heart failure. It compares patients who get the sensor to those who receive standard care, to see if the sensor improves outcomes.
Naperville, IllinoisAges 18 years+ - NCT06787612RecruitingPhase 2
New combination for platinum-resistant ovarian cancer
This study tests a new combination treatment (ubamatamab plus another drug) for people with ovarian cancer that no longer responds to platinum chemotherapy. It could be an option if your cancer has kept growing despite prior treatment.
Birmingham, AlabamaAges 18 years+ - NCT06788756RecruitingPhase 2/Phase 3
Testing L-Annamycin plus Cytarabine for relapsed AML
This trial tests whether the combination of two chemotherapy drugs, L-Annamycin and Cytarabine, can help adults whose acute myeloid leukemia (AML) has come back or not responded to one prior treatment. The goal is to see if this combination can lead to remission.
Birmingham, AlabamaAges 18–80 - NCT06782971Recruiting
Testing a new combination for AML with high blast cells
This trial is testing a combination of venetoclax and azacitidine in people with acute myeloid leukemia (AML) who have a high percentage of blast cells (at least 20%) in their bone marrow or blood. It aims to see if this treatment approach can improve outcomes for patients regardless of previous treatments or transplant history.
Canberra, Australian Capital TerritoryAges 18 years+ - NCT06395402RecruitingPhase 2
Personalized dosing of lutathera for neuroendocrine tumors
This trial tests a personalized way to give a radioactive drug called Lutathera to people with neuroendocrine tumors (NETs). The goal is to see if adjusting the dose based on how your body absorbs it can be more effective.
Iowa City, IowaAges 18 years+ - NCT06786832Recruiting
Trial for fatigued patients in primary care
This trial studies severe fatigue that started at a specific time and is not due to another illness. It aims to find better ways to diagnose, treat, and support people with long-term fatigue in primary care.
Stockholm, GustavsbergAges 18–67 - NCT06789588Enrolling by invitationPhase 3
Better warfarin therapy for atrial fibrillation
This study tests a better way to manage warfarin (a blood thinner) for people with atrial fibrillation (an irregular heartbeat). The goal is to improve treatment and help prevent stroke.
Recife, PernambucoAges 18 years+ - NCT06785298RecruitingPhase 2/Phase 3
Fexofenadine as add-on treatment for Parkinson's disease
This trial tests whether adding fexofenadine, a common allergy medicine, to your current Parkinson's treatment can help improve symptoms. It's for people aged 50 or older who are already on dopamine replacement therapy.
TantaAges 50–70
Hear when a new Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for therapy?
- Yes. Clin2 currently lists 7,173 recruiting therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.